Feasibility and acceptability outcomes of the InMe trial - a randomised controlled trial in participants with subclinical eating and somatic symptom disorders
Abstract
Dysregulations in interoception have been associated with mental health disorders including eating and somatic symptom disorders. The present study addresses the feasibility and acceptability of a novel, behavioural intervention (InMe) in a healthy sample with low, self-reported interoception. The efficacy of the InMe intervention against an active control arm was tested in a randomised controlled trial (RCT) reported elsewhere, while the feasibility and acceptability of InMe were assessed in parallel and are fully reported here. Participants were randomly assigned to the intervention arm (InMe) or active control arm and stratified according to their self-reported gender and a cut-off score from the Eating Disorders Questionnaire (EDE-Q). Feasibility and accessibility measures included self-report scales and questionnaires, assessor checklists and ratings, as well as behavioural and physiological responses. Data was gathered from a total of 102 participants and encompassed trial recruitment and retention rates, the suitability of measurement tools, as well as the feasibility and acceptability of stressors, interventions and other trial procedures. The study found satisfactory feasibility in recruitment procedures, trial measurement tools, and intervention procedures. Participants perceived the intervention as acceptable, though minor adjustments for trial optimisation were identified. Overall, this feasibility study provided promising evidence regarding the acceptability and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 102 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.